Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07211867 · ClinicalTrials.gov registry record · NA
A Digital Intervention to Decrease Self-Stigma Among Pregnant and Postpartum Women With Substance Use Disorder
A NA study of Substance Use Disorder, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT07211867: Recruiting NA study of Substance Use Disorder, sponsored by Washington University School of Medicine.
NCT07211867 is a NA study of Substance Use Disorder that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 152 participants, below the 814-participant average among 18 other Substance Use Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07211867, a NA study of Substance Use Disorder, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
Digital interventions have the potential to support healthier behaviors among pregnant and postpartum women (PPW) with substance use disorders (SUDs) and may also provide a promising method for reducing their self-stigma. Enhearten is a digital intervention designed to foster adherence to medications for addiction treatment (MAT) while considering the unique needs of PPW, but its effects on self-stigma, treatment retention, and SUD outcomes have not been rigorously tested. The investigators will conduct an individual-level multicenter randomized controlled trial to test the feasibility, acceptability, and efficacy of Enhearten on reducing self-stigma and on improving SUD treatment and recovery outcomes with a stigma-focused ecological momentary intervention (EMI) designed to: 1) screen for feelings of stigma and 2) counteract these vulnerabilities among PPW with SUD via just-in-time interventions.
Primary Outcome
Participants in each group will be assessed on levels of perceived self-stigma using the Brief Substance Use Stigma Scale ). The Brief Substance Use Stigma Scale uses a 5-point Likert scale, ranging from "strongly disagree" to "strongly agree". Mean scores will be created with higher scores indicating higher levels of stigma.
Conditions Studied
Interventions
- BEHAVIORAL Waitlist Control Group
- BEHAVIORAL Enhearten with EMI
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2025-11-24 |
| Est. Completion | 2027-05 |
| Phase | NA |
What NCT07211867 shows while recruiting
NCT07211867 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 814-participant average among 18 other Substance Use Disorder trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Substance Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Waitlist Control Group is the first listed.
NCT07211867 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07211867 about?
NCT07211867 is a clinical study titled "A Digital Intervention to Decrease Self-Stigma Among Pregnant and Postpartum Women With Substance Use Disorder". Digital interventions have the potential to support healthier behaviors among pregnant and postpartum women (PPW) with substance use disorders (SUDs) and may also provide a promising method for reducing their self-stigma. Enhearten is a digital intervention designed to foster adherence to medication...
What is the current status of trial NCT07211867?
This trial is currently recruiting. It is a NA study. The enrollment target is 152 participants. The study started on 2025-11-24. Estimated completion is 2027-05.
What conditions does trial NCT07211867 study?
This clinical trial studies the following conditions: Substance Use Disorder.
What interventions are being tested in trial NCT07211867?
The interventions under investigation include: Waitlist Control Group (BEHAVIORAL), Enhearten with EMI (BEHAVIORAL).
Who is sponsoring clinical trial NCT07211867?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07211867 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07211867's enrollment target sits among peer trials
152 10th of 18 higher than 9 of 18 other Substance Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
A Type I Hybrid Effectiveness-Implementation Trial of MIO
RECRUITING · NA
-
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
RECRUITING · NA
-
Personalized Approach to Healthy Use and Recovery (PATH) Trial
RECRUITING · NA
-
Defining Neurobiological Links Between Substance Use and Mental Illness
RECRUITING · NA
-
Successful Transitions and Reintegration Tools for Veterans (START-VETS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI